Liposaccharide natural compounds consisting of a trisaccharide repeating unit (two heptose units and octulosonic acid) with oligosaccharide side chains and 3-hydroxytetradecanoic acid units (they are a major constituent of the cell walls of Gram-negative bacteria).
Chemical ID:
MESH:D008070
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form; [Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of BCL2 protein; [Silicon Dioxide co-treated with Lipopolysaccharides] results in decreased expression of BCL2 mRNA; [TNFAIP3 gene mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of BCL2 mRNA; AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in decreased expression of BCL2 mRNA]; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]; Carticaine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; CASP1 protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in decreased expression of BCL2 mRNA]; CASP1 protein affects the reaction [AHR protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in decreased expression of BCL2 mRNA]]; catalpol inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; Dexamethasone inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; Fluoxetine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein]; MYD88 protein affects the reaction [[TNFAIP3 gene mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of BCL2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; palmatine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; sesamol affects the reaction [Lipopolysaccharides affects the expression of BCL2 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]; Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of BCL2 protein]; zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; [Diosmin co-treated with Lipopolysaccharides] results in increased expression of BCL2 protein; Apigenin inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; Bezafibrate inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2 protein]; ferulic acid inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; Honghua extract, Carthamus tinctorius inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; MIR17 mRNA affects the reaction [ferulic acid inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; PTEN protein inhibits the reaction [ferulic acid inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; Sialic Acids inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; tetramethylpyrazine inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2 protein]; Tigecycline inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]
(+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2 mRNA]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [catalpol inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; [Dehydroascorbic Acid co-treated with Lipopolysaccharides] results in increased expression of BCL2 protein; adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide promotes the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; alpha-Tocopherol affects the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; catalpol inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; Cilostazol inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; daphnetin inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; FANCA mRNA alternative form affects the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; KR-31612 affects the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; MIR17 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; N''-cyano-N-(6-amino-3,4-dihydro-3-hydroxy-2-methyl-2-dimethoxymethyl-2H-benzopyran-4-yl)-N'-benzylguanidine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; NEAT1 affects the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; PCNA affects the reaction [FANCA mRNA alternative form affects the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; puerarin inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; SIRT1 protein affects the reaction [catalpol inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; TLR4 protein inhibits the reaction [NEAT1 affects the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; TRPM7 protein inhibits the reaction [MIR17 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]
